An observational study in Necrotizing Soft-tissue Infections, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million.
The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.
28 studies on the registry are indexed under Fasciitis, Necrotizing; 8 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 152 across 16 observational studies indexed under Fasciitis, Necrotizing.
Browse Fasciitis, Necrotizing studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients (adults and children) with a suspected or confirmed necrotizing soft-tissue infections (NSTI) managed within the SURFAST care pathway.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
mortality
If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator
Time frame: 90 days
hospital mortality
vital status measured at hospital discharge
Time frame: at hospital discharge and within 60 days of hospital admission
time from hospital admission to first surgical debridement
time period measured in hours between first hospital admission and first surgical debridement
Time frame: within the first 72 hours of hospital admission
functional outcome and quality of life
measured using the Activity of Daily Living (ADL) and the EQ-5D-5L (EuroQol) French version scores
Time frame: day 90 post-admission
amputation rate
toe or limb amputation performed
Time frame: day 90
annual case volume per centre
number of NSTI cases managed per year in each centre participating in the SURFAST network
Time frame: 123 months
bacteriological documentation
bacterial documentation of NSTIs obtained from blood cultures or cultures of operative tissue samples.
Time frame: At the time of blood culture collection or operative tissue sampling
Plan to share: No — DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Jun 2036, 123 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →